Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie různých sekvencí Cilta-cel, Talquetamabu v kombinaci s daratumumabem a Teclistamabu v kombinaci s daratumumabem po indukci daratumumabem, bortezomibem, lenalidomidem a dexamethasonem u účastníků se standardním rizikem nově diagnostikovaného mnohočetného myelomu (aMMbition)

2. listopadu 2026 aktualizováno: Janssen Research & Development, LLC

Fáze 2, otevřená studie k vyhodnocení účinnosti a bezpečnosti různých sekvencí ciltacabtagene autoleucelu (Cilta-cel), talquetamabu SC v kombinaci s daratumumabem SC (Tal-D) a Teclistamabu SC v kombinaci s daratumumabem SC (Tec-D ) Po indukci daratumumabem, bortezomibem, lenalidomidem a dexamethasonem (DVRd) u účastníků se standardním rizikem nově diagnostikovaného mnohočetného myelomu

The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

43

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Melbourne, Austrálie, 3004
        • The Alfred Hospital
      • Melbourne, Austrálie, 3000
        • Peter MacCallum Cancer Centre
      • Salvador, Brazílie, 41253-190
        • IDOR - Regional Bahia
      • São Paulo, Brazílie, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brazílie, 05652 900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • Heidelberg, Německo, 69120
        • Universitaetsklinikum Heidelberg
      • Tübingen, Německo, 72076
        • Universitaetsklinikum Tuebingen
      • Würzburg, Německo, 97080
        • Universitatsklinikum Wurzburg
    • California
      • Duarte, California, Spojené státy, 91010
        • City of Hope
      • San Francisco, California, Spojené státy, 94143
        • University of California San Francisco
    • Iowa
      • Iowa City, Iowa, Spojené státy, 52242
        • University of Iowa Hospital and Clinics
    • New York
      • New York, New York, Spojené státy, 10065
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Charlotte, North Carolina, Spojené státy, 28204
        • Levine Cancer Institute
      • Madrid, Španělsko, 28041
        • Hosp. Univ. 12 de Octubre
      • Salamanca, Španělsko, 37007
        • Hosp Clinico Univ de Salamanca
      • Santander, Španělsko, 39008
        • Hosp. Univ. Marques de Valdecilla

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 70 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Participants with documented new diagnosis of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy
  • Participants must have standard-risk MM (stage I and II) based on revised International Staging System (R-ISS)
  • Participants must be considered fit (score equals to [=] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living)
  • Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) (>=10 gram per liter [g/L] for institutions using alternative units) or urine M-protein level >= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1

Exclusion Criteria:

  • Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy
  • Peripheral neuropathy or neuropathic pain of Grade >= 2, as defined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  • Known active or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
  • Stroke or seizure within 6 months of signing the informed consent form (ICF)
  • Plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (>= 5 percent [%] circulating plasma cells in peripheral blood smears), Waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(POEMS) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction
  • Presence of high-risk disease features: (a) Cytogenetic high risk lesions by MM fluorescence in situ hybridization (FISH) including deletion 17p (del[17p])/, t(4;14), t(14;16), amplification 1q (amp[1q21]) (>= 4 copies); (b) Presence of 1 or more extramedullary plasmacytomas
  • Seropositive for human immunodeficiency virus (HIV)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel

Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release, and completion of induction, participants will begin consolidation with 4 cycles of Tal-D (each cycle is of 28 days), followed by a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days); cilta-cel will be administered 5 to 7 days after the start of the conditioning regimen.

Talquetamab will be administered subcutaneously.

Ostatní jména:
  • JNJ-64407564

Cilta-cel infusion will be administered intravenously.

Ostatní jména:
  • JNJ-68284528, Ciltacabtagene autoleucel

Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.

Ostatní jména:
  • JNJ-54767414

Bortezomib will be administered subcutaneously as a part of induction.

Lenalidomide will be administered orally as a part of induction.

Dexamethasone will be administered orally as a part of induction.

Cyclophosphamide will be administered intravenously as a part of conditioning regimen.

Fludarabine will be administered intravenously as a part of conditioning regimen.

Experimentální: Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation

Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release and completion of induction, participants will begin consolidation with a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days) with infusion of cilta-cel 5 to 7 days after the start of the conditioning regimen. Following cilta-cel infusion, alternating cycles of Tal-D (Cycle 1, 3, 5, and 7) and Tec-D (Cycle 2, 4, 6, and 8) will be started, no earlier than Day 84 and no later than Day 168 post cilta-cel infusion. Each cycle of Tal-D or Tec-D is 84 days which includes an extended treatment-free interval.

Talquetamab will be administered subcutaneously.

Ostatní jména:
  • JNJ-64407564

Teclistamab will be administered subcutaneously.

Ostatní jména:
  • JNJ-64007957

Cilta-cel infusion will be administered intravenously.

Ostatní jména:
  • JNJ-68284528, Ciltacabtagene autoleucel

Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.

Ostatní jména:
  • JNJ-54767414

Bortezomib will be administered subcutaneously as a part of induction.

Lenalidomide will be administered orally as a part of induction.

Dexamethasone will be administered orally as a part of induction.

Cyclophosphamide will be administered intravenously as a part of conditioning regimen.

Fludarabine will be administered intravenously as a part of conditioning regimen.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Rate of Response with Curative Potential
Časové okno: Up to 5 years

Rate of Response with curative potential is defined as the percentage of participants with a composite of durable (at least 2 years) minimal residual disease (MRD) (10^-5) negativity with complete response/stringent complete response (CR/sCR) by serology and negative positron emission tomography/computed tomography (PET/CT) imaging at 5-years after start of induction therapy. This includes: negative imaging at 5-year landmark time; MRD-negative status (at 10^-5) in 2 bone marrow examinations that are a minimum of 2 years apart; response of CR or better per the International Myeloma Working Group (IMWG) criteria; no examination showing MRD-positive status or relapse from CR in between assessments.

Up to 5 years
Progression Free Survival (PFS) Rate at 3-Year
Časové okno: At 3-year

PFS is defined as the time from the date of randomization to either progressive disease (PD), according to the IMWG response criteria, or death, whichever occurs first.

At 3-year
PFS Rate at 5-Year
Časové okno: At 5-year

PFS is defined as the time from the date of randomization to either PD, according to the IMWG response criteria, or death, whichever occurs first.

At 5-year

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Overall response rate (ORR; Partial response [PR] or better)
Časové okno: Up to 5 years

ORR (PR or better) is defined as the percentage of participants with best overall response of PR or better according to IMWG response criteria.

Up to 5 years
CR or Better Rate
Časové okno: Up to 5 years

Rate of CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria.

Up to 5 years
Very Good Partial Response (VGPR) or Better Rate
Časové okno: Up to 5 years

Rate of VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria.

Up to 5 years
Duration of Response (DOR)
Časové okno: Up to 5 years

DOR is calculated among responders (with a PR or better response) from the date of initial documented response (PR or better) to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first.

Up to 5 years
Time to First Response (TTR)
Časové okno: Up to 5 years

Time to response (that is, time to first response) is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better based on the computerized algorithm per IMWG criteria for those who had PR or better as their best response.

Up to 5 years
Duration of CR or Better Response
Časové okno: Up to 5 years

Duration of CR or better response is calculated among responders (with a CR or better response) from the date of initial documented response CR or better to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first.

Up to 5 years
Time to First CR or Better Response
Časové okno: Up to 5 years

Time to first CR or better response is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for CR or better based on the computerized algorithm per IMWG criteria.

Up to 5 years
PFS on next line therapy (PFS2)
Časové okno: Up to 5 years

PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first.

Up to 5 years
Overall Survival (OS)
Časové okno: Up to 5 years

OS is measured from the date of randomization to the date of death due to any cause.

Up to 5 years
MRD-negative CR Rate
Časové okno: Up to 5 years

MRD-negative CR is defined as the percentage of participants who achieved both CR or better and MRD negativity at a threshold of 10^-5 and 10^-6. MRD-negative CR rate will be evaluated at the first occurrence from induction treatment initiation for participants per IMWG criteria.

Up to 5 years
Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity
Časové okno: Up to 5 years

An Adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events.

Up to 5 years
Change from baseline in Health-related quality of life (HRQoL) (symptoms and functioning) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 item instrument (EORTC-QLQ-C30)
Časové okno: Up to 5 years

Change from baseline in participants' HRQoL (symptoms and functioning) as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0-to-100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.

Up to 5 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

20. srpna 2024

Primární dokončení (Odhadovaný)

2. září 2030

Dokončení studie (Odhadovaný)

30. září 2030

Termíny zápisu do studia

První předloženo

27. srpna 2024

První předloženo, které splnilo kritéria kontroly kvality

27. srpna 2024

První zveřejněno (Aktuální)

29. srpna 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 54767414MMY2093
  • 54767414MMY2093 (Jiný identifikátor: Janssen Research & Development, LLC)
  • 2023-505792-71-00 (Identifikátor registru: EUCT number)
  • 2023 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .